Sulfonylcarboxamide derivatives, process for their...

Details Sulfonylcarboxamide derivatives, process for their... Sulfonylcarboxamide derivatives, process for their...

2000-09-01

2002-01-29

Raymond, Richard L. (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S331000, C514S603000, C514S604000, C546S208000, C546S234000, C564S085000, C564S086000, C564S089000, C564S090000, C564S091000, C564S092000, C544S145000, C544S357000, C544S359000

Reexamination Certificate

active

06342512

ABSTRACT:

This application claims benefit under 35 U.S.C. §119 of application No. 19941540.4-44 filed on Sep. 1, 1999 and application No. 10027611.3 of Jun. 6, 2000 in Germany, which are hereby incorporated by reference.
The invention relates to sulfonylcarboxamide derivatives and their physiologically acceptable salts and physiologically functional derivatives and to their use for preparing medicines for the prevention and treatment of hyperlipidemia and arteriosclerotic disorders.
Sulfonylcarboxamides have already been described In Chemical Abstracts 96, 142393m (1982).
In DE 2145686, 2-chloro-5-sulfamylbenzoic acid derivatives have already been described as lipid-lowering agents.
The invention is based on the object of providing further compounds which have a therapeutically utilizable hypolipidemic action. In this context, the object was, in particular, also to provide compounds having an increased hypolipidemic action compared to the 2-chloro-5-sulfamylbenzoic acid derivatives from DE 2145686.
Accordingly, the invention relates to compounds of the formula I
in which
X, R1, R2, R3 are, independently of one another, NR6R7, (CH
2
)-pyridyl, (CH
2
)
n
-phenyl, where n can be 0-6 and the phenyl radical can be substituted up to two times by F, Cl, Br, CF
3
, NH
2
, CN, OCF
3
, O—(C
1
-C
6
)-alkyl, S—(C
1
-C
6
)-alkyl, (C
1
-C
6
)-alkyl, (C
3
-C
6
)-cycloalkyl, COO(C
1
-C
6
)-alkyl, COO(C
3
-C
6
)-cycloalkyl, CONH
2
, CONH(C
1
-C
6
)alkyl, CON[(C
1
-C
6
)alkyl]
2
;
(C
1
-C
8
)-alkyl, pyrrolidinyl, piperidinyl, piperazinyl, 2-oxopiperazinyl, morpholinyl, tetrahydropyridinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, it being possible for each of the rings to be substituted by phenyl, (C
1
-C
6
)-alkyl-phenyl, —OH, (C
1
-C
8
)-alkyl, (C
1
-C
6
)-alkyl-OH, O-phenyl, S-phenyl, (CO)—(C
1
-C
6
)-alkyl, (CO)-phenyl, where the phenyl substituent is unsubstituted or substituted up to two times by F, Cl, Br, OH, CF
3
, CN, OCF
3
, O—(C
1
-C
6
)-alkyl, S—(C
1
-C
6
)-alkyl, SO—(C
1
-C
6
)-alkyl, SO
2
—(C
1
-C
6
)-alkyl, (C
1
-C
6
)-alkyl, (C
3
-C
6
)-cycloalkyl, COOH, COO(C
1
-C
6
)alkyl, COO(C
3
-C
6
)cycloalkyl, CONH
2
, CONH(C
1
-C
6
)alkyl, CON[(C
1
-C
6
)alkyl]
2
, CONH(C
3
-C
6
)cycloalkyl, NH
2
, NH—CO—(C
1
-C
6
)-alkyl, NH—CO-phenyl;
R6 and R7 are, independently of one another, H, (C
1
-C
6
)-alkyl, (C
1
-C
6
)-alkyl—OH, (C
1
-C
6
)-alkyl-NH2, (C
1
-C
6
)-alkyl-O—(C
1
-C
6
)-alkyl, O—(C
1
-C
6
)-alkyl, (C
3
-C
6
)-cycloalkyl, CO—(C
1
-C
6
)-alkyl, (C
1
-C
6
)-alkyl-NH—C(O)—(C
1
-C
6
)-alkyl, (C
1
-C
6
)-alkyl-NH—(C
1
-C
6
)-alkyl, (C
1
-C
6
)-alkyl-N—[(C
1
-C
6
)-alkyl]
2
, (C
1
-C
6
)-alkyl-di-phenyl, (C
1
-C
6
)-alkyl-O-phenyl, CHO, CO-phenyl,
 (CH
2
)
n
—Ar, where n can be 0-6, and Ar can be equal to phenyl, biphenylyl, 1- or 2-naphthyl, 1- or 2-tetrahydrofuranyl, 2-, 3- or 4-pyridyl, 2- or 3-thienyl, 2- or 3-furyl, 2-, 4- or 5-thiazolyl, 2-, 4- or 5-oxazolyl, 1-pyrazolyl, 3-, 4- or 5-isoxazolyl, (C
3
-C
6
)-cycloalkyl, piperidinyl, pyrrolidinyl, oxopyridyl, 2- or 3-pyrrolyl, 2- or 3-pyridazinyl, 2-, 4- or 5-pyrimidinyl, 2-pyrazinyl, 2-(1,3,5-triazinyl), 2-, 3- or 4-morpholinyl, 2- or 5-benzimidazolyl, 2-benzothiazolyl, 1,2,4-triazol-3-yl, 1,2,4-triazol-5-yl, tetrazol-5-yl, indol-3-yl, indol-5-yl or N-methylimidazol-2-, -4- or -5-yl and Ar can be substituted up to two times by F, Cl, Br, OH, CF
3
, NO
2
, CN, OCF
3
, O—CH
2
—O, O—(C
1
-C
6
)-alkyl, S—(C
1
-C
6
)-alkyl, SO—(C
1
-C
6
)-alkyl, SO
2
—(C
1
-C
6
)-alkyl, (C
1
-C
6
)-alkyl, (C
3
-C
6
)-cycloalkyl, COOH, COO(C
1
-C
6
)alkyl, COO(C
3
-C
6
)cycloalkyl, CONH
2
, CONH(C
1
-C
6
)alkyl, CON[(C
1
-C
6
)alkyl]
2
, CONH(C
3
-C
6
)cycloalkyl, NH
2
, NH—CO—(C
1
-C
6
)-alkyl, NH—CO-phenyl, pyrrolidin-1-yl, morpholin-1-yl, piperidin-1-yl, piperazin-1-yl, 4-methylpiperazin-1-yl, (CH
2
)
n
-phenyl, O—(CH
2
)
n
-phenyl, S—(CH
2
)
n
-phenyl, SO
2
—(CH
2
)
n
-phenyl, where n=0-3;
and their physiologically acceptable salts.
Preference is given to compounds of the formula I in which one or more radical(s) is/are as defined below:
R1, R2 are, independently of one another, NR6R7, pyrrolidinyl, piperidinyl, piperazinyl, tetrahydropyridyl, it being possible for each of the rings to be substituted by phenyl, (C
1
-C
6
)-alkyl-phenyl, (C
1
-C
6
)-alkyl, (C
1
-C
6
)-alkyl-OH, O-phenyl, S-phenyl, (CO)—(C
1
-C
6
)-alkyl, (CO)-phenyl, where the phenyl substituent is unsubstituted or substituted up to two times by F, Cl, Br, CF
3
, CN, OCF
3
, O—(C
1
-C
6
)-alkyl, S-(C
1
-C
6
)-alkyl, (C
1
-C
6
)-alkyl, (C
3
-C
6
)-cycloalkyl, COOH, COO(C
1
-C
6
)-alkyl, COO(C
3
-C
6
)cycloalkyl, CONH
2
, CONH(C
1
-C
6
)alkyl, CON[(C
1
-C
6
)alkyl]
2
, NH
2
, NH—CO—(C
1
-C
6
)-alkyl, NH—CO-phenyl;
R6, R7 are, independently of one another, H, (C
1
-C
6
)-alkyl, (C
1
-C
6
)-alkyl-O—(C
1
-C
6
)-alkyl, (C
3
-C
6
)-cycloalkyl, CO—(C
1
-C
6
)-alkyl, (C
1
-C
6
)-alkyl-NH—C(O)—(C
1
-C
6
)-alkyl, (C
1
-C
6
)-alkyl-NH—(C
1
-C
6
)-alkyl, (C
1
-C
6
)-alkyl-N—[(C
1
-C
6
)-alkyl]
2
,
 (CH
2
)
n
—Ar, where n can be 0-6 and Ar can be equal to phenyl, biphenylyl, 1- or 2-naphthyl, 2-, 3- or 4-pyridyl, 2- or 3-thienyl, 2-, 4- or 5-thiazolyl, 2-, 4- or 5-oxazolyl, 3- or 5-isoxazolyl, (C
3
-C
6
)-cycloalkyl, piperidinyl, pyrrolidinyl, 2-, 4- or 5-pyrimidinyl, 2-, 3- or 4-morpholinyl, 2- or 5-benzimidazolyl, 2-benzothiazolyl or indol-3-yl, indol-5-yl and Ar can be substituted up to two times by F, Cl, Br, OH, CF
3
, NO
2
, CN, OCF
3
, O—(C
1
-C
6
)-alkyl, S—(C
1
-C
6
)-alkyl, SO—(C
1
-C
6
)-alkyl, SO
2
—(C
1
-C
6
)-alkyl, (C
1
-C
6
)-alkyl, (C
3
-C
6
)-cycloalkyl, COOH, COO(C
1
-C
6
)alkyl, COO(C
3
-C
6
)cycloalkyl, CONH
2
, CONH(C
1
-C
6
)alkyl, NH
2
, NH—CO-phenyl, (CH
2
)
n
-phenyl, O—(CH
2
)
n
-phenyl, S—(CH
2
)
n
-phenyl, where n=0-3;
X, R3 are, independently of one another, NR8R9, pyrrolidinyl, piperidinyl, morpholinyl, (C
1
-C
8
)-alkyl, (CH
2
)
n
-phenyl, where n=0-6 and the phenyl radical can be substituted up to two times by F, Cl, Br, CF
3
, CN, OCF
3
, O—(C
1
-C
6
)-alkyl, S—(C
1
-C
6
)-alkyl, (C
1
-C
6
)-alkyl, (C
3
-C
6
)-cycloalkyl, COO(C
1
-C
6
)-alkyl, COO(C
3
-C
6
)cycloalkyl, CONH
2
, CONH(C
1
-C
6
)alkyl, CON[(C
1
-C
6
)alkyl]
2
;
R8, R9 are, independently of one another, H, (C
1
-C
6
)-alkyl, (C
3
-C
6
)-cycloalkyl, CO—(C
1
-C
6
)-alkyl, (C
1
-C
6
)-alkyl-CO—(C
1
-C
6
)-alkyl, SO
2
-benzyl, SO
2
-benzyl-OCH
3
, (CH
2
)
n
—Ar, where n can be 0-6 and Ar can be equal to phenyl or thienyl and Ar can be substituted up to two times by F, Cl, Br, CF
3
, NO
2
, CN, OCF
3
, O—CH
2
—O, O—(C
1
-C
6
)-alkyl, S—(C
1
-C
6
)-alkyl, SO—(C
1
-C
6
)-alkyl, SO
2
—(C
1
-C
6
)-alkyl, (C
1
-C
6
)-alkyl, (C
3
-C
6
)-cycloalkyl, NH—CO-phenyl, (CH
2
)
n
-phenyl, O—(CH
2
)
n
-phenyl, S—(CH
2
)
n
-phenyl, SO
2
—(CH
2
)
n
-phenyl, where n=0-2;
and their physiologically acceptable salts.
Particular preference is given to compounds of the formula I in which one or more radical(s) is/are as defined below:
R1, R2 are, independently of one another, NR6R7, piperidinyl, piperazinyl, tetrahydropyridyl, it being possible for each of the rings to be substituted by phenyl, (C
1
-C
6
)-alkyl-phenyl, (C
1
-C
6
)-alkyl, (CO)—(C
1
-C
6
)-alkyl;
R6, R7 are, independently of one another, H, (C
1
-C
6
)-alkyl, (C
1
-C
6
)-alkyl-NH—(C
1
-C
6
)-alkyl, (C
1
-C
6
)-alkyl-N—[(C
1
-C
6
)-alkyl]
2
, (CH
2
)
n
—Ar, where n can be 0-6 and Ar can be equal to phenyl, 2-, 3- or 4-pyridyl, piperidinyl, pyrrolidinyl, 2-, 4- or 5-pyrimidinyl, 2-, 3- or 4-morpholinyl and Ar can be substituted up to two times by F, Cl, Br, OH, CF
3
, NO
2
, CN, OCF
3
, O—(C
1
-C
6
)-alkyl, (C
1
-C
6
)-alkyl, COOH, NH
2
,(CH
2
)
n
-phenyl, where n can be 0-3;
X is NR8R9, piperazinyl, (C
1
-C
6
)-alkyl, (CH
2
)
n
-phenyl, where n can be 0-6;
R3 is NR10R11, piperazinyl;
R8, R9 are, independently of one another, H, (C
1
-C
6
)-alkyl, (C
3
-C
6
)-cycloalkyl, CO—(C
1
-C
6
)-alkyl, (C
1
-C
6
)-alkyl-CO—(C
1
-C
6
)-alkyl, SO
2
-benzyl, SO
2
-benzyl-OCH
3
, (CH
2
)
n
—Ar, where n can be 0-6 and Ar can be equal to phenyl or thienyl;
R10, R11 a

Affiliated with

Also associated with

Rating

Sulfonylcarboxamide derivatives, process for their... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Sulfonylcarboxamide derivatives, process for their..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Sulfonylcarboxamide derivatives, process for their... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2862710